- Home
- All Stock List
- NSE
- Emcure Pharmaceuticals Ltd Share Price
1,072.40
23.15 (2.21%)
-
Underperforms Index
0%
Return (1Y)
Underperformed Nifty 500 by 5.35%
-
More Volatile
2.32%
Standard Deviation (1Y)
Higher than Nifty 500 by 1.33%
-
Not so consistent
5/9
Months
underperformed Nifty 500
-
AxisDirect View
No View
1,580
911
News & Announcements
-
Emcure Pharmaceuticals announced its entry into the daily supplements space with the expansion of its Arth range. With a comprehensive approach to holistic well-being, Arth offers a wide range of supplements that harness the power of ancient Indian herbs like Brahmi, with the precision of modern science to address key health concerns that are often overlooked. As an initiative within its broader efforts for quality and women's health education, Emcure has partnered with acclaimed actor and women's health advocate Vidya Balan as the brand ambassador for its Arth range. A respected household name across the nation, Vidya will spark conversations around less discussed and important aspects of health, including inmate care and sleep issues, encouraging women to prioritize and take charge of their health.
As a part of the association, Vidya will spotlight three key products from the Arth range: Inmate Care to soothe itchiness and dryness in inmate areas, Sleep Support Gummies for blissful and quality sleep; Brain Fog Aid to improve focus and support cognition.
Powered by Capital Market - Live News
-
Emcure's API unit completes USFDA inspection
33 days ago
Emcure Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) had conducted a current Good Manufacturing Practices (cGMP) inspection of Company's API manufacturing facility located at M.I.D.C., Kurkumbh, Taluka - Daund, Pune - 413802, Maharashtra, from 19 February 2025 to 25 February 2025. On conclusion of the inspection, the Company received two observations in Form 483.
Powered by Capital Market - Live News
-
According to an exchange filing, the inspection was conducted at the company’s Active Pharmaceutical Ingredient (API) manufacturing facility located at M.I.D.C., Kurkumbh, Maharashtra, from 19 February 2025 to 25 February 2025. At the conclusion of the inspection, the company received two observations in Form 483.
The company has stated that it is addressing the observations comprehensively and will respond to the USFDA within the required timeframe.
Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.
The company’s consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024.
The counter rose 0.96% to settle at Rs 988.80 on Tuesday, 25 February 2025. The stock market is closed today on account of Mahashivratri.
Powered by Capital Market - Live News
-
Emcure's API unit completes USFDA inspection
33 days ago
Emcure Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) had conducted a current Good Manufacturing Practices (cGMP) inspection of Company's API manufacturing facility located at M.I.D.C., Kurkumbh, Taluka - Daund, Pune - 413802, Maharashtra, from 19 February 2025 to 25 February 2025. On conclusion of the inspection, the Company received two observations in Form 483.
Powered by Capital Market - Live News
-
According to an exchange filing, the inspection was conducted at the company’s Active Pharmaceutical Ingredient (API) manufacturing facility located at M.I.D.C., Kurkumbh, Maharashtra, from 19 February 2025 to 25 February 2025. At the conclusion of the inspection, the company received two observations in Form 483.
The company has stated that it is addressing the observations comprehensively and will respond to the USFDA within the required timeframe.
Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.
The company’s consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024.
The counter rose 0.96% to settle at Rs 988.80 on Tuesday, 25 February 2025. The stock market is closed today on account of Mahashivratri.
Powered by Capital Market - Live News
-
Emcure Pharmaceuticals consolidated net profit rises 35.50% in the December 2024 quarter
53 days ago
Emcure Pharmaceuticals consolidated net profit rises 35.50% in the December 2024 quarter
06 - Feb - 2025 12:00 | 53 days ago
Net profit of Emcure Pharmaceuticals rose 35.50% to Rs 153.72 crore in the quarter ended December 2024 as against Rs 113.45 crore during the previous quarter ended December 2023. Sales rose 17.69% to Rs 1962.63 crore in the quarter ended December 2024 as against Rs 1667.64 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 1962.63 1667.64 18 OPM % 18.07 18.41 - PBDT 326.73 262.01 25 PBT 229.92 177.62 29 NP 153.72 113.45 35 Powered by Capital Market - Live News
-
Emcure Pharmaceuticals announced its entry into the daily supplements space with the expansion of its Arth range. With a comprehensive approach to holistic well-being, Arth offers a wide range of supplements that harness the power of ancient Indian herbs like Brahmi, with the precision of modern science to address key health concerns that are often overlooked. As an initiative within its broader efforts for quality and women's health education, Emcure has partnered with acclaimed actor and women's health advocate Vidya Balan as the brand ambassador for its Arth range. A respected household name across the nation, Vidya will spark conversations around less discussed and important aspects of health, including inmate care and sleep issues, encouraging women to prioritize and take charge of their health.
As a part of the association, Vidya will spotlight three key products from the Arth range: Inmate Care to soothe itchiness and dryness in inmate areas, Sleep Support Gummies for blissful and quality sleep; Brain Fog Aid to improve focus and support cognition.
Powered by Capital Market - Live News
-
Emcure's API unit completes USFDA inspection
33 days ago
Emcure Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) had conducted a current Good Manufacturing Practices (cGMP) inspection of Company's API manufacturing facility located at M.I.D.C., Kurkumbh, Taluka - Daund, Pune - 413802, Maharashtra, from 19 February 2025 to 25 February 2025. On conclusion of the inspection, the Company received two observations in Form 483.
Powered by Capital Market - Live News
-
According to an exchange filing, the inspection was conducted at the company’s Active Pharmaceutical Ingredient (API) manufacturing facility located at M.I.D.C., Kurkumbh, Maharashtra, from 19 February 2025 to 25 February 2025. At the conclusion of the inspection, the company received two observations in Form 483.
The company has stated that it is addressing the observations comprehensively and will respond to the USFDA within the required timeframe.
Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.
The company’s consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024.
The counter rose 0.96% to settle at Rs 988.80 on Tuesday, 25 February 2025. The stock market is closed today on account of Mahashivratri.
Powered by Capital Market - Live News
-
Emcure Pharmaceuticals consolidated net profit rises 35.50% in the December 2024 quarter
53 days ago
Emcure Pharmaceuticals consolidated net profit rises 35.50% in the December 2024 quarter
06 - Feb - 2025 12:00 | 53 days ago
Net profit of Emcure Pharmaceuticals rose 35.50% to Rs 153.72 crore in the quarter ended December 2024 as against Rs 113.45 crore during the previous quarter ended December 2023. Sales rose 17.69% to Rs 1962.63 crore in the quarter ended December 2024 as against Rs 1667.64 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 1962.63 1667.64 18 OPM % 18.07 18.41 - PBDT 326.73 262.01 25 PBT 229.92 177.62 29 NP 153.72 113.45 35 Powered by Capital Market - Live News
-
Emcure Pharmaceuticals announced its entry into the daily supplements space with the expansion of its Arth range. With a comprehensive approach to holistic well-being, Arth offers a wide range of supplements that harness the power of ancient Indian herbs like Brahmi, with the precision of modern science to address key health concerns that are often overlooked. As an initiative within its broader efforts for quality and women's health education, Emcure has partnered with acclaimed actor and women's health advocate Vidya Balan as the brand ambassador for its Arth range. A respected household name across the nation, Vidya will spark conversations around less discussed and important aspects of health, including inmate care and sleep issues, encouraging women to prioritize and take charge of their health.
As a part of the association, Vidya will spotlight three key products from the Arth range: Inmate Care to soothe itchiness and dryness in inmate areas, Sleep Support Gummies for blissful and quality sleep; Brain Fog Aid to improve focus and support cognition.
Powered by Capital Market - Live News
-
Emcure's API unit completes USFDA inspection
33 days ago
Emcure Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) had conducted a current Good Manufacturing Practices (cGMP) inspection of Company's API manufacturing facility located at M.I.D.C., Kurkumbh, Taluka - Daund, Pune - 413802, Maharashtra, from 19 February 2025 to 25 February 2025. On conclusion of the inspection, the Company received two observations in Form 483.
Powered by Capital Market - Live News
-
According to an exchange filing, the inspection was conducted at the company’s Active Pharmaceutical Ingredient (API) manufacturing facility located at M.I.D.C., Kurkumbh, Maharashtra, from 19 February 2025 to 25 February 2025. At the conclusion of the inspection, the company received two observations in Form 483.
The company has stated that it is addressing the observations comprehensively and will respond to the USFDA within the required timeframe.
Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.
The company’s consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024.
The counter rose 0.96% to settle at Rs 988.80 on Tuesday, 25 February 2025. The stock market is closed today on account of Mahashivratri.
Powered by Capital Market - Live News
-
Emcure's API unit completes USFDA inspection
33 days ago
Emcure Pharmaceuticals announced that the United States Food and Drug Administration (USFDA) had conducted a current Good Manufacturing Practices (cGMP) inspection of Company's API manufacturing facility located at M.I.D.C., Kurkumbh, Taluka - Daund, Pune - 413802, Maharashtra, from 19 February 2025 to 25 February 2025. On conclusion of the inspection, the Company received two observations in Form 483.
Powered by Capital Market - Live News
-
According to an exchange filing, the inspection was conducted at the company’s Active Pharmaceutical Ingredient (API) manufacturing facility located at M.I.D.C., Kurkumbh, Maharashtra, from 19 February 2025 to 25 February 2025. At the conclusion of the inspection, the company received two observations in Form 483.
The company has stated that it is addressing the observations comprehensively and will respond to the USFDA within the required timeframe.
Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.
The company’s consolidated net profit surged 35.5% to Rs 153.72 crore in Q3 FY25 as against Rs 113.45 crore posted in Q3 FY24. Revenue from operations jumped 17.7% YoY to Rs 1,962.63 crore in the quarter ended 31 December 2024.
The counter rose 0.96% to settle at Rs 988.80 on Tuesday, 25 February 2025. The stock market is closed today on account of Mahashivratri.
Powered by Capital Market - Live News
-
Emcure Pharmaceuticals consolidated net profit rises 35.50% in the December 2024 quarter
53 days ago
Emcure Pharmaceuticals consolidated net profit rises 35.50% in the December 2024 quarter
06 - Feb - 2025 12:00 | 53 days ago
Net profit of Emcure Pharmaceuticals rose 35.50% to Rs 153.72 crore in the quarter ended December 2024 as against Rs 113.45 crore during the previous quarter ended December 2023. Sales rose 17.69% to Rs 1962.63 crore in the quarter ended December 2024 as against Rs 1667.64 crore during the previous quarter ended December 2023.
Particulars Quarter Ended Dec. 2024 Dec. 2023 % Var. Sales 1962.63 1667.64 18 OPM % 18.07 18.41 - PBDT 326.73 262.01 25 PBT 229.92 177.62 29 NP 153.72 113.45 35 Powered by Capital Market - Live News
Stock Trivia
FII shareholding in Emcure Pharmaceuticals Ltd has increased by 4.85% since past 3 Months
MF shareholding in Emcure Pharmaceuticals Ltd has decreased by -6.22% since past 3 Months
FII shareholding in Emcure Pharmaceuticals Ltd has increased by 4.85% since past 3 Months
MF shareholding in Emcure Pharmaceuticals Ltd has decreased by -6.22% since past 3 Months
FII shareholding in Emcure Pharmaceuticals Ltd has increased by 4.85% since past 3 Months
MF shareholding in Emcure Pharmaceuticals Ltd has decreased by -6.22% since past 3 Months
